Updated time: 2023-12-21 11:42:09
12A-1061221
JP 7230035、TW I818943、US 11,813,326B2
The present invention adopts nanocarriers to facilitate intracellular delivery of immunologic adjuvants to cancer cells, thereby prompting anticancer immune responses following cancer treatments.
Nanoparticle-mediated intracellular delivery of immunologic adjuvants renders adjuvant administration safer and more potent at eliciting antigen-specific immune responses.
The present invention can be applied to a large number of cancer types and combined with existing anticancer treatments.
Che-Ming Jack Hu, Saborni Chattopadhyay
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Pathogenic cell-associating immunologic adjuvants for treatment enhancement